Scarica l'app Stockscreener
1.20
11.11%
0.12
Pre-mercato:
1.30
0.10
+8.33%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HUMA Giù?
Forum
Previsione
Humacyte Inc Borsa (HUMA) Ultime notizie
Patterns Watch: Can Humacyte Inc stock deliver sustainable ROESwing Trade & Risk Managed Investment Signals - moha.gov.vn
Is Humacyte, Inc. (HUMA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Humacyte rises on Symvess sale to military treatment facility - MSN
Humacyte jumps as DoD issues ECAT listing approval for Symvess - MSN
Humacyte Announces Planned Marketing Authorization Application for Symvess in Israel - MarketScreener
Humacyte Inc announces planned marketing authorization application for Symvess in Israël - MarketScreener
D. Boral Capital Reiterates "Buy" Rating for Humacyte (NASDAQ:HUMA) - MarketBeat
Humacyte plans to seek approval for vessel product in Israel - Investing.com
Humacyte plans to seek approval for vessel product in Israel By Investing.com - Investing.com UK
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel - The Manila Times
Rate Hike: Is Humacyte Inc stock attractive for income investorsDollar Strength & Daily Entry Point Trade Alerts - moha.gov.vn
Humacyte, Inc. (NASDAQ:HUMA) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why Is Humacyte, Inc. (HUMAW) Stock Down Today? - Meyka
Can Humacyte Inc. Equity Warrant stock maintain growth trajectoryChart Pattern Recognition & Compound Your Gains With Quality Stocks - Bollywood Helpline
Humacyte's (HUMA) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Humacyte Reports High Limb Salvage Rates and Durability of Symvess in Long-Term Study Published in JVS-CIT - Quiver Quantitative
Off-the-shelf blood vessel implant helps save injured limbs in study - Stock Titan
Humacyte announces credit facility of $77.5M with Avenue Capital - MSN
Regulatory Ruptures For A Lab-Grown Blood Vessel - The Lever
Lab-Grown Blood Vessel Maker Promotes Risky Off-Label Uses - Jacobin
Humacyte terminates revenue interest agreement - MSN
Humacyte (NASDAQ:HUMA) Stock Rating Lowered by Wall Street Zen - MarketBeat
Is Humacyte Inc. stock attractive for income investorsEarnings Risk Summary & Detailed Earnings Play Strategies - DonanımHaber
Can Humacyte Inc. stock surprise with earnings upsideWeekly Trade Summary & High Accuracy Investment Entry Signals - bolumsonucanavari.com
What catalysts could drive Humacyte Inc. Equity Warrant stock higher2025 Market Outlook & Real-Time Volume Trigger Notifications - DonanımHaber
Is Humacyte Inc. Equity Warrant stock a contrarian buy2025 Breakouts & Breakdowns & Safe Capital Growth Plans - DonanımHaber
Can Humacyte Inc. Equity Warrant stock beat market expectations this quarterQuarterly Growth Report & Daily Profit Maximizing Trade Tips - ulpravda.ru
Published on: 2025-12-19 01:36:49 - Улправда
Is Humacyte Inc. Equity Warrant stock affected by interest rate hikesCEO Change & Reliable Breakout Forecasts - Улправда
Aug Chart Watch: Can Humacyte Inc. Equity Warrant stock beat market expectations this quarterInsider Buying & Capital Efficient Trading Techniques - Улправда
Humacyte enters sales agreement with TD Securities - MSN
Humacyte's US$28m Market Cap Fall Books Insider Losses - simplywall.st
Humacyte’s Big Promise Still Faces A Rocky Road - Finimize
Humacyte Enters Sales Agreement with TD Securities - TipRanks
Humacyte may offer and sell shares of common stock of up to $60 million from time to time through TD Cowen, acting as agent - marketscreener.com
Humacyte (NASDAQ: HUMA) details $60M at the market stock offering - Stock Titan
[424B5] Humacyte, Inc. Prospectus Supplement (Debt Securities) - Stock Titan
Investment Review: Is Humacyte Inc Equity Warrant stock a contrarian buyJuly 2025 Short Interest & Expert Curated Trade Setups - moha.gov.vn
Humacyte secures up to $77.5 million credit facility with Avenue Capital - Investing.com Nigeria
Humacyte secures $77.5 million loan facility - MSN
Humacyte announces credit facility of up to $77.5 million with Avenue Capital - marketscreener.com
Humacyte Signs $77.5 Million Credit Facility - marketscreener.com
Humacyte Secures $77.5 Million Credit Facility with Avenue Venture Opportunities Fund to Support Growth and Development Initiatives - Quiver Quantitative
Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital - marketscreener.com
Humacyte, Inc. Announces Credit Facility of Up to $77.5 Million with Avenue Capital - marketscreener.com
Total debt per share of Humacyte, Inc. Warrant 2021-27.08.26 on Humacyte – NASDAQ:HUMAW - TradingView — Track All Markets
Humacyte Secures $77.5 Million Loan Facility - TipRanks
[8-K] Humacyte, Inc. Reports Material Event | HUMA SEC FilingForm 8-K - Stock Titan
Humacyte terminates revenue interest purchase agreement - marketscreener.com
Humacyte Terminates Revenue Interest Agreement - TipRanks
Humacyte (NASDAQ: HUMA) to issue 5.7M shares, pay $38M to end deal - Stock Titan
Wall Street Zen Upgrades Humacyte (NASDAQ:HUMA) to "Hold" - MarketBeat
Is Humacyte Inc a good long term investmentStraddle and Strangle Trades & Explosive Capital Growth Plans - earlytimes.in
Humacyte (HUMA): Benchmark remains bullish on stock - MSN
Humacyte Stock (HUMA) Opinions on FDA Approval for Symvess Product - Quiver Quantitative
Humacyte (HUMA): Benchmark Remains Bullish on Stock - Finviz
28.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):